China's Degron Therapeutics is one of a select few biotech start-ups to grab investors’ attention recently, while many of its peers have been struggling to raise new funds.
The Shanghai-based venture, founded only in April 2021, develops small molecule compounds in the hot new area of targeted protein...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

